PTC596

A BMI1 inhibitor

此产品仅用于科学研究，我们不为任何个人用途提供产品和服务

库存: 现货

可选规格

包装

价格

促销价

数量
1mg

￥1125.00

900.00

- +
5mg

￥3262.00

2610.00

- +
10mg

￥4962.00

3970.00

- +
25mg

￥7337.00

5870.00

- +
50mg

￥10737.00

8590.00

- +
100mg

￥17850.00

14280.00

- +
200mg

￥0.00

0.00

- +
500mg

￥0.00

0.00

- +

已选 0 种 0 瓶

金额: ￥0.00

首页收藏

货号: ajcx15024
CAS: 1610964-64-1
别名: PTC596
分子式: C19H13F5N6
分子量: 420.34
纯度: >98%
溶解度: DMF: 30 mg/ml,DMSO: 30 mg/ml,Ethanol: 5 mg/ml
储存: Store at -20°C
库存: 现货

Background

PTC-596 is an inhibitor of B cell-specific Moloney murine leukemia virus integration site 1 (BMI1), which is a member of the polycomb repressive complex 1 (PRC1) that has a role in gene silencing.^1,2 It inhibits proliferation of MOLM-13 acute myeloid leukemia (AML) and Rec-1 mantle cell lymphoma (MCL) cancer cells (IC₅₀s = 22.4 and 136 nM, respectively). It also induces BMI1 degradation in, and apoptosis of, the same cells. PTC-596 reduces microtubule polymerization and induces cell cycle arrest at the G₂/M phase in MM.1S multiple myeloma cells.³ It decreases the number of side population cells, a unique cell population with stem-like characteristics, in Rec-1 cells (IC₅₀ = 138 nM).² PTC-596 (5 mg/kg, p.o.) increases survival in a MOLM-13 mouse xenograft model.¹

1.Nishida, Y., Maeda, A., Kim, M.J., et al.The novel BMI-1 inhibitor PTC596 downregulates MCL-1 and induces p53-independent mitochondrial apoptosis in acute myeloid leukemia progenitor cellsBlood Cancer J.7(2)e527(2017) 2.Maeda, A., Nishida, Y., Weetall, M., et al.Targeting of BMI-1 expression by the novel small molecule PTC596 in mantle cell lymphomaOncotarget.9(47)28547-28560(2018) 3.Nagai, Y., Mimura, N., Rizq, O., et al.The combination of the tubulin binding small molecule PTC596 and proteasome inhibitors suppresses the growth of myeloma cellsSci. Rep.11(1)2074(2021)